Life Sciences

Watch now for an event releasing a report by ITIF, the Geneva Network, and the University of Akron School of Law profiling 24 pioneering case studies from five regions—Latin America, Africa, South Asia, Southeast Asia, and Middle East and North Africa—where IP rights have enabled innovators to create impactful health solutions, particularly in the developing world.

Again and again, America has pioneered new technologies and then frittered away its leadership—in sectors ranging from semiconductors and solar panels, to televisions and medical devices. We can’t afford to squander another lead in multi-cancer early detection (MCED) because of regulatory roadblocks.

Many of the world’s biggest challenges are health challenges. The good news is that, more than ever, people are meeting these challenges with innovative solutions.

AI has the potential to transform drug development by enhancing productivity across the entire development pipeline, boosting biopharmaceutical innovation, accelerating the delivery of new therapies, and fostering competition to help improve public health outcomes.

This event will feature keynotes and panels with speakers from GTIPA member organizations; experts on trade, globalization, innovation, and IP policy issues; and leaders from India’s business, academic, and policymaking communities.

The UK government needs to make a choice: competitiveness and growth or heavy-handed regulation in the service of social policy. It can have one but not both.

Mario Draghi's 2024 report addresses the EU's biopharmaceutical decline, citing challenges like underfunded research, fragmented pricing, and competition from the U.S. and China. It recommends reforms but underplays the impact of EU drug price controls on innovation.

The Information Technology and Innovation Foundation will offer grants for new research that helps to inform the relationship between the expectation of a financial reward for an approved new drug or new indication in the United States and the (1) investment in research and development for new and existing drugs, and/or (2) the approval of new drugs and new indications.

TauRx is revolutionizing Alzheimer's treatment with a novel drug that targets toxic brain proteins, offering fresh hope in the fight against this devastating disease.

Despite popular rhetoric around the supposedly exorbitant prices of prescription drugs, the price of pharmaceutical products has increased far slower than the rate of inflation.